The Academy: July/August 2007
The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing farther in pursuit of knowledge and new discoveries. In this issue we highlight presentations from the 43rd annual ASCO meeting as well as research being done at Massachusetts General Hospital and Dana-Farber Cancer Institute in Boston and the University of Texas Southwestern Medical Center in Dallas.
Physicians' Financial News for July/August 2007
Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) GlaxoSmithKline 2) Ventana Medical Systems Inc. and Roche Holding AG, and more
Clinical Abstracts From Overseas: July 7, 2010
Among the articles provided in this issue are topics presented at the 43rd annual meeting of the American Society of Clinical Oncology.
Clinical Trial Reports: July/August 2007
Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more
Reimbursement and Managed Care News: July/August 2007
In this issue we highlight topics presented at the 43rd annual meeting of the American Society of Clinical Oncology: 1) Focus Groups and Advisory Boards: To What Extent Do They Supplement Oncologists' Income? 2) The High Overhead Cost of Complying With National Guidelines, and more
Swiss Approve Brain Cancer Vaccine
According to the U.S. National Cancer Institute, there are 19,000 new cases of primary brain cancer diagnosed each year. The five-year survival rate is around 30%. Brain cancers can strike all ages, and are the leading cause of cancer deaths in children under the age of 20.
Reporting from ASCO
At ASCO's 43rd annual meeting in Chicago, more than 4,000 abstracts were presented, and 25,000 specialists from around the world convened to hear the latest advances in cancer treatment.
The Extended ASCO Coverage Issue
This issue of Oncology & Biotech News presents some of the most noteworthy and newsworthy information from the 43rd annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512